These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7803250)

  • 21. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1995 Jul; 74(1):139-48. PubMed ID: 8578447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders.
    Dahlbäck B
    Int J Lab Hematol; 2016 May; 38 Suppl 1():4-11. PubMed ID: 27161771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early days of APC resistance and FV Leiden.
    Dahlbäck B
    Hamostaseologie; 2008; 28(3):103-9. PubMed ID: 18521487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
    Castaman G; Ruggeri M; Tosetto A; Rodeghiero F
    Am J Hematol; 1998 Apr; 57(4):344-7. PubMed ID: 9544982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
    Dahlbck B
    J Intern Med Suppl; 1997; 740():1-8. PubMed ID: 9350175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
    Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
    Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The discovery of activated protein C resistance.
    Dahlbäck B
    J Thromb Haemost; 2003 Jan; 1(1):3-9. PubMed ID: 12871530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
    Zöller B; Svensson PJ; He X; Dahlbäck B
    J Clin Invest; 1994 Dec; 94(6):2521-4. PubMed ID: 7989612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Resistance to activated protein C. The most common cause of familial thrombophilia].
    Larsen TB; Ravn HB; Lassen JF; Lund ED; Brandslund I
    Ugeskr Laeger; 1996 Nov; 158(46):6584-8. PubMed ID: 8966822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated protein C resistance due to a factor V mutation associated with familial ischemic stroke.
    De Lucia D; Nina P; Papa ML; Belli A; Conte M; Renis V; Di Mauro C; Masi S; Franco A; Schisano G
    J Neurosurg Sci; 1997 Dec; 41(4):373-8. PubMed ID: 9555645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls.
    Voelkerding KV; Wu L; Williams EC; Hoffman SM; Sabatini LM; Borcherding WR; Huber S
    Am J Clin Pathol; 1996 Jul; 106(1):100-6. PubMed ID: 8701917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis.
    Dahlbäck B; Hillarp A; Rosen S; Zöller B
    Ann Hematol; 1996 Apr; 72(4):166-76. PubMed ID: 8624369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis.
    Mandel H; Brenner B; Berant M; Rosenberg N; Lanir N; Jakobs C; Fowler B; Seligsohn U
    N Engl J Med; 1996 Mar; 334(12):763-8. PubMed ID: 8592550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
    Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
    Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes of resistance to activated protein C in the course of pregnancy and prevalence of factor V mutation.
    Mimuro S; Lahoud R; Beutler L; Trudinger B
    Aust N Z J Obstet Gynaecol; 1998 May; 38(2):200-4. PubMed ID: 9653861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1997 Jul; 78(1):483-8. PubMed ID: 9198201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries.
    Holm J; Zöller B; Berntorp E; Erhardt L; Dahlbäck B
    J Intern Med; 1996 Mar; 239(3):221-6. PubMed ID: 8772620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.